Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT), highlighting its potential as a treatment option ...
Among patients treated in the first-line setting, the overall response rate was 57.1%, compared with 38.1% in those treated in the second line or later.
COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE® CLL-1 trial (NCT04623541) evaluating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback